The Anti-CDMO with CTMC's Jason Bock, Ph.D. and KSQ's Thomas Leitch

This isn't your typical drug sponsor + CDMO story. In fact, CTMC's Jason Bock, Ph.D. says you shouldn't even classify his company as a CDMO. He's not wrong. While some of the company's services aren't dissimilar from those offered by a contract developer, CTMC began with a more fundamental mission in mind -- to help early clinical-stage companies like KSQ Therapeutics prepare for and enter their clinical stage on the best possible footing, and with the best possible clinical partner in the MD Anderson Cancer Center. On this episode of the Business of Biotech, KSQ's Thomas Leitch and Dr. Bock join us to share the story of CTMC's evolution, KSQ's partnership needs as it advanced its lead phase 1 TIL therapy for solid tumors, how the partnership unfolded, and who's on the hook for what as KSQ begins its clinical journey.
You've listened along for years -- now you can watch along, too! Go to bioprocessonline.com/solution/the-business-of-biotech-podcast, where you can put faces to voices as you watch hundreds of interviews with the world's best biotech builders. While you're there, subscribe to the #BusinessofBiotech newsletter at bioprocessonline.com/bob for more real, honest, transparent interactions with the leaders of emerging biotech. It's a once-per-month dose of insight and intel that you'll actually look forward to receiving! Check it out at bioprocessonline.com/bob!
---
#businessofbiotech #biopharma #biotech
Subscribe to the podcast:
Apple - podcasts.apple.com/us/podcast...
Spotify - open.spotify.com/show/5NhjpDe...
TH-cam - • The Business Of Biotec...